Eevia Health

On May 28, Terry Virts informed the Board of his resignation to pursue a political career in his home country. His departure was intended to be addressed at a planned Extraordinary General Meeting (EGM) scheduled for May 30, where a new Chairman would be elected. However, due to sick leave among key participants and the absence of shareholders at the meeting, the EGM was never legally convened. This “no-show” was not promptly reported to the public and caused that the vacancy was not filled. When the AGM was also delayed, the issue was prolonged over the summer, while the various issues were also not properly reported to the public due to capacity issues in the Administration. The resignation was later registered with the Finnish Patent and Registration Office (PRH) on July 2, but a clerical error incorrectly listed Per Benjaminsen as Chairman, which is being corrected with PRH.

Furthermore, in January 2025, the Board appointed Marinus Sørensen to fill a vacancy, believing this to be permissible under the Finnish Limited Liability Companies Act. However, questions were later raised about whether such appointments can only be made by a General Meeting as stipulated by the Finnish Companies Act. As reported earlier, the Board consider that the state in the Limited Liability Companies Act dominates the Company Act, but due to a miscommunication with the person undertaking PRH registration back in February, Mr. Sørensen’s appointment was never formally registered with the Finnish Patent and Registration Office, despite being announced publicly. This issue was also supposed to be handled through elections in the planned EGM, or secondarily in the AGM. However, since both meetings are not yet held, only three of the Board’s four current members are formally registered with PRH.

Eevia are resolving these issues by updating registrations with the authorities and ensuring that the upcoming General Meeting elects a chairman and the required number of Board members. The current Board remains operational, is self-organizing and will appoint an Interim Chairman from among its members to lead proceedings until the General Meeting.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc is a health ingredient company specialized in sustainable bioactive extracts from wild-harvested Nordic plants and berries. With a focus on gut health, including kidney and urinary health, as well as cellular protection, and inflammation, Eevia offers clinically relevant ingredients to global nutraceutical brands.

Eevia Health, founded in 2017, is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.